Hydrocodone controlled-release - Pernix Therapeutics

Drug Profile

Hydrocodone controlled-release - Pernix Therapeutics

Alternative Names: AFI-001; Hydrocodone bitartrate; Hydrocodone ER; Hydrocodone extended release; Zohydro ER; ZX 007; ZX-002

Latest Information Update: 31 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daravita
  • Developer Zogenix
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 29 Jan 2018 Pernix Therapeutics has pending patent litigation against Alvogen Malta Operations over proposed generic version of Zohydro® ER in the US District Court for the District of Delaware
  • 29 Jan 2018 Pernix Therapeutics Holdings enters into patent litigation settlement agreement with Actavis related to Actavis’s submission of an Abbreviated New Drug Application for a generic version of Zohydro® ER in USA
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pain(In volunteers) in USA (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top